Tech Company Financing Transactions
Upstream Bio Funding Round
Upstream Bio, based in Waltham, received $200 million from Enavate Sciences, Venrock and Access Biotechnology.
Transaction Overview
Company Name
Announced On
6/10/2023
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
460 Totten Pond Rd. 420
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Samantha Truex
Chief Medical Officer
Aaron Deykin
Co-Founder
Oren Becker
VP - Bus. Development
Jen Beachell
VP - Bus. Development
Adam Houghton
VP - Finance
Robert Prentiss
Browse more venture capital transactions:
Prev: 6/9/2023: Ohanafy venture capital transaction
Next: 6/12/2023: Truvity venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs